Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-06-28

AUTHORS

Axel Berthelot, Celine Bequet, Vincent Harlay, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Romain Appay, Olivier Chinot, Emeline Tabouret

ABSTRACT

BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7–87.5). Median KPS was 60 (range 30–100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+ ratio was 2.11 (range 0.54–9.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+ ratio tended to be different between refractory (PD patients) and non-refractory patients (p = 0.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5–22.9) and 43.2 (95%CI 21.6–64.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+ ratio > 1.97 was associated with poor PFS [p = 0.043, HR = 3.32 (1.02–4.88)] and tended to be associated with worse OS (p = 0.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients. More... »

PAGES

15-22

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5

DOI

http://dx.doi.org/10.1007/s11060-022-04032-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149025622

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35763119


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Subsets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large B-Cell, Diffuse", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berthelot", 
        "givenName": "Axel", 
        "id": "sg:person.013514371275.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013514371275.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bequet", 
        "givenName": "Celine", 
        "id": "sg:person.01366075341.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366075341.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harlay", 
        "givenName": "Vincent", 
        "id": "sg:person.013546622047.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013546622047.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrirena", 
        "givenName": "Gregorio", 
        "id": "sg:person.0721565704.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721565704.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Campello", 
        "givenName": "Chantal", 
        "id": "sg:person.0646537516.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646537516.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barri\u00e9", 
        "givenName": "Maryline", 
        "id": "sg:person.01012432765.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012432765.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "APHM, CHU Timone, Service d\u2019anatomopathologie, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
            "APHM, CHU Timone, Service d\u2019anatomopathologie, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Appay", 
        "givenName": "Romain", 
        "id": "sg:person.011205067533.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011205067533.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.464051.2", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chinot", 
        "givenName": "Olivier", 
        "id": "sg:person.0704465355.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704465355.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.411266.6", 
          "name": [
            "APHM, CHU Timone, Service de Neurooncologie, Marseille, France", 
            "Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France", 
            "Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tabouret", 
        "givenName": "Emeline", 
        "id": "sg:person.01160514623.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160514623.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-020-02575-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1127141873", 
          "https://doi.org/10.1007/s00262-020-02575-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-007-9397-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052553767", 
          "https://doi.org/10.1007/s11060-007-9397-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-021-04474-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1135850698", 
          "https://doi.org/10.1007/s00277-021-04474-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-28", 
    "datePublishedReg": "2022-06-28", 
    "description": "BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7\u201387.5). Median KPS was 60 (range 30\u2013100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+\u2009ratio was 2.11 (range 0.54\u20139.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+\u2009ratio tended to be different between refractory (PD patients) and non-refractory patients (p\u2009=\u20090.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5\u201322.9) and 43.2 (95%CI 21.6\u201364.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+\u2009ratio\u2009>\u20091.97 was associated with poor PFS [p\u2009=\u20090.043, HR\u2009=\u20093.32 (1.02\u20134.88)] and tended to be associated with worse OS (p\u2009=\u20090.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-022-04032-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "159"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "overall survival", 
      "lymphocyte subsets", 
      "progressive disease", 
      "prognostic value", 
      "primary central nervous system lymphoma", 
      "median progression-free survival", 
      "poor progression-free survival", 
      "central nervous system lymphoma", 
      "ResultsFifty-three patients", 
      "worse overall survival", 
      "nervous system lymphoma", 
      "non-refractory patients", 
      "presence of steroids", 
      "median KPS", 
      "PCNSL patients", 
      "partial response", 
      "refractory disease", 
      "chemotherapy administration", 
      "median age", 
      "system lymphoma", 
      "predictive factors", 
      "CNS DLBCL", 
      "B lymphopenia", 
      "blood lymphocytes", 
      "normal lip", 
      "patients", 
      "predictive value", 
      "treatment data", 
      "multivariate analysis", 
      "lymphopenia", 
      "disease", 
      "survival", 
      "KPS", 
      "lip results", 
      "rituximab", 
      "lip analysis", 
      "lymphoma", 
      "lymphocytes", 
      "ObjectiveTo", 
      "steroids", 
      "MethodsWe", 
      "administration", 
      "NK", 
      "baseline", 
      "subset", 
      "months", 
      "important role", 
      "median", 
      "age", 
      "refractory", 
      "lip", 
      "response", 
      "ratio", 
      "factors", 
      "role", 
      "analysis", 
      "presence", 
      "values", 
      "data", 
      "institutions", 
      "development", 
      "results"
    ], 
    "name": "Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma", 
    "pagination": "15-22", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149025622"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-022-04032-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35763119"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-022-04032-5", 
      "https://app.dimensions.ai/details/publication/pub.1149025622"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_926.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-022-04032-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04032-5'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      101 URIs      90 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-022-04032-5 schema:about N1da1a4d9e462424aa2e669c046ff514b
2 N1dfbfdc1da814d21a47244a40e35a735
3 N54f00eee07634dca88044c2dc174f7d8
4 N5cd638a6dbb649d08e869958353e4df8
5 N6fa38a422a244c98a9009b947091b0ad
6 N7b8a6aa9ccdf479190cba0c74cac52c0
7 N9c509496e35641c5bac87dbe5ecc6041
8 Nb55af048b01e49c2beaedfaa58c21e7f
9 Nd6ce0219eab64a74a82820fcdb6b7813
10 Ndbb0a515172646da8d2b9ab58e46a68a
11 anzsrc-for:11
12 anzsrc-for:1109
13 schema:author Nc091d9cbca5c416d8fc45bb4d3d353eb
14 schema:citation sg:pub.10.1007/s00262-020-02575-y
15 sg:pub.10.1007/s00277-021-04474-3
16 sg:pub.10.1007/s11060-007-9397-0
17 schema:datePublished 2022-06-28
18 schema:datePublishedReg 2022-06-28
19 schema:description BackgroundImmunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.ObjectiveTo evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.MethodsWe prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.ResultsFifty-three patients were included with a median age of 69.7 (range 21.7–87.5). Median KPS was 60 (range 30–100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+ ratio was 2.11 (range 0.54–9.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+ ratio tended to be different between refractory (PD patients) and non-refractory patients (p = 0.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5–22.9) and 43.2 (95%CI 21.6–64.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+ ratio > 1.97 was associated with poor PFS [p = 0.043, HR = 3.32 (1.02–4.88)] and tended to be associated with worse OS (p = 0.064).ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N70945fe83cec4cc3b382b2c0f8bce4d4
23 N89f9327d1fd344c1bb0c5ebfbd290d6d
24 sg:journal.1094205
25 schema:keywords B lymphopenia
26 CNS DLBCL
27 KPS
28 MethodsWe
29 NK
30 ObjectiveTo
31 PCNSL patients
32 ResultsFifty-three patients
33 administration
34 age
35 analysis
36 baseline
37 blood lymphocytes
38 central nervous system lymphoma
39 chemotherapy administration
40 data
41 development
42 disease
43 factors
44 important role
45 institutions
46 lip
47 lip analysis
48 lip results
49 lymphocyte subsets
50 lymphocytes
51 lymphoma
52 lymphopenia
53 median
54 median KPS
55 median age
56 median progression-free survival
57 months
58 multivariate analysis
59 nervous system lymphoma
60 non-refractory patients
61 normal lip
62 overall survival
63 partial response
64 patients
65 poor progression-free survival
66 predictive factors
67 predictive value
68 presence
69 presence of steroids
70 primary central nervous system lymphoma
71 prognostic value
72 progression-free survival
73 progressive disease
74 ratio
75 refractory
76 refractory disease
77 response
78 results
79 rituximab
80 role
81 steroids
82 subset
83 survival
84 system lymphoma
85 treatment data
86 values
87 worse overall survival
88 schema:name Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma
89 schema:pagination 15-22
90 schema:productId N27d5829b168b4544adc1d0c316dd239a
91 N55a5da0c92b84a419c28b68684a18515
92 N6eb1447bdb654d6096e35c71ac31494e
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149025622
94 https://doi.org/10.1007/s11060-022-04032-5
95 schema:sdDatePublished 2022-12-01T06:43
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Naf9d3958cc704bdcad16fa4562e2e332
98 schema:url https://doi.org/10.1007/s11060-022-04032-5
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N1521eb7923ae4c47a0325c43067cdd65 rdf:first sg:person.011205067533.95
103 rdf:rest N5ac89a47f1154e8d9930e2c92e8ec2c5
104 N1801b6b0501447508ecb942ef1a1e5e3 rdf:first sg:person.01366075341.14
105 rdf:rest N75d838a251034e1aadf174b3961c8aec
106 N1da1a4d9e462424aa2e669c046ff514b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antineoplastic Combined Chemotherapy Protocols
108 rdf:type schema:DefinedTerm
109 N1dfbfdc1da814d21a47244a40e35a735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Prognosis
111 rdf:type schema:DefinedTerm
112 N27d5829b168b4544adc1d0c316dd239a schema:name doi
113 schema:value 10.1007/s11060-022-04032-5
114 rdf:type schema:PropertyValue
115 N54f00eee07634dca88044c2dc174f7d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N55a5da0c92b84a419c28b68684a18515 schema:name dimensions_id
119 schema:value pub.1149025622
120 rdf:type schema:PropertyValue
121 N5ac89a47f1154e8d9930e2c92e8ec2c5 rdf:first sg:person.0704465355.32
122 rdf:rest Nf3981c99575449a5b8229fab0f9fc34a
123 N5cd638a6dbb649d08e869958353e4df8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Lymphocyte Subsets
125 rdf:type schema:DefinedTerm
126 N6eb1447bdb654d6096e35c71ac31494e schema:name pubmed_id
127 schema:value 35763119
128 rdf:type schema:PropertyValue
129 N6fa38a422a244c98a9009b947091b0ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Retrospective Studies
131 rdf:type schema:DefinedTerm
132 N70945fe83cec4cc3b382b2c0f8bce4d4 schema:issueNumber 1
133 rdf:type schema:PublicationIssue
134 N752446a5c2304b7fbe972f887d32ab6d rdf:first sg:person.0721565704.73
135 rdf:rest Nf0b84b17b55946adaa76822f92c76dad
136 N75d838a251034e1aadf174b3961c8aec rdf:first sg:person.013546622047.13
137 rdf:rest N752446a5c2304b7fbe972f887d32ab6d
138 N7b8a6aa9ccdf479190cba0c74cac52c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Lymphocyte Count
140 rdf:type schema:DefinedTerm
141 N89f9327d1fd344c1bb0c5ebfbd290d6d schema:volumeNumber 159
142 rdf:type schema:PublicationVolume
143 N9c509496e35641c5bac87dbe5ecc6041 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Central Nervous System
145 rdf:type schema:DefinedTerm
146 Naf9d3958cc704bdcad16fa4562e2e332 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Nb55af048b01e49c2beaedfaa58c21e7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Lymphopenia
150 rdf:type schema:DefinedTerm
151 Nc091d9cbca5c416d8fc45bb4d3d353eb rdf:first sg:person.013514371275.39
152 rdf:rest N1801b6b0501447508ecb942ef1a1e5e3
153 Nd6ce0219eab64a74a82820fcdb6b7813 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Rituximab
155 rdf:type schema:DefinedTerm
156 Ndbb0a515172646da8d2b9ab58e46a68a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Lymphoma, Large B-Cell, Diffuse
158 rdf:type schema:DefinedTerm
159 Nf0b84b17b55946adaa76822f92c76dad rdf:first sg:person.0646537516.22
160 rdf:rest Nfb7b28cff283472d92e7112589b07c6d
161 Nf3981c99575449a5b8229fab0f9fc34a rdf:first sg:person.01160514623.82
162 rdf:rest rdf:nil
163 Nfb7b28cff283472d92e7112589b07c6d rdf:first sg:person.01012432765.90
164 rdf:rest N1521eb7923ae4c47a0325c43067cdd65
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
169 schema:name Neurosciences
170 rdf:type schema:DefinedTerm
171 sg:journal.1094205 schema:issn 0167-594X
172 1573-7373
173 schema:name Journal of Neuro-Oncology
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01012432765.90 schema:affiliation grid-institutes:grid.411266.6
177 schema:familyName Barrié
178 schema:givenName Maryline
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012432765.90
180 rdf:type schema:Person
181 sg:person.011205067533.95 schema:affiliation grid-institutes:grid.411266.6
182 schema:familyName Appay
183 schema:givenName Romain
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011205067533.95
185 rdf:type schema:Person
186 sg:person.01160514623.82 schema:affiliation grid-institutes:grid.411266.6
187 schema:familyName Tabouret
188 schema:givenName Emeline
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160514623.82
190 rdf:type schema:Person
191 sg:person.013514371275.39 schema:affiliation grid-institutes:grid.411266.6
192 schema:familyName Berthelot
193 schema:givenName Axel
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013514371275.39
195 rdf:type schema:Person
196 sg:person.013546622047.13 schema:affiliation grid-institutes:grid.411266.6
197 schema:familyName Harlay
198 schema:givenName Vincent
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013546622047.13
200 rdf:type schema:Person
201 sg:person.01366075341.14 schema:affiliation grid-institutes:grid.411266.6
202 schema:familyName Bequet
203 schema:givenName Celine
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366075341.14
205 rdf:type schema:Person
206 sg:person.0646537516.22 schema:affiliation grid-institutes:grid.411266.6
207 schema:familyName Campello
208 schema:givenName Chantal
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646537516.22
210 rdf:type schema:Person
211 sg:person.0704465355.32 schema:affiliation grid-institutes:grid.464051.2
212 schema:familyName Chinot
213 schema:givenName Olivier
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704465355.32
215 rdf:type schema:Person
216 sg:person.0721565704.73 schema:affiliation grid-institutes:grid.411266.6
217 schema:familyName Petrirena
218 schema:givenName Gregorio
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721565704.73
220 rdf:type schema:Person
221 sg:pub.10.1007/s00262-020-02575-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1127141873
222 https://doi.org/10.1007/s00262-020-02575-y
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s00277-021-04474-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135850698
225 https://doi.org/10.1007/s00277-021-04474-3
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s11060-007-9397-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052553767
228 https://doi.org/10.1007/s11060-007-9397-0
229 rdf:type schema:CreativeWork
230 grid-institutes:grid.411266.6 schema:alternateName APHM, CHU Timone, Service de Neurooncologie, Marseille, France
231 APHM, CHU Timone, Service d’anatomopathologie, Marseille, France
232 Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France
233 schema:name APHM, CHU Timone, Service de Neurooncologie, Marseille, France
234 APHM, CHU Timone, Service d’anatomopathologie, Marseille, France
235 Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
236 Neuro-Oncology Department, University Hospital La Timone, 264 rue Saint Pierre, 13005, Marseille, France
237 rdf:type schema:Organization
238 grid-institutes:grid.464051.2 schema:alternateName Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
239 schema:name APHM, CHU Timone, Service de Neurooncologie, Marseille, France
240 Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...